Multiple Sclerosis Treatment Becomes Canada’s First MS Stem Cell Clinical Trial.

The University of Ottawa trial infuses MSCs to reduce inflammation in the central nervous systems of MS patients.

The Multiple Sclerosis Society of Canada has funded Canada’s first stem cell clinical trial to treat multiple sclerosis, conducted by researchers at the University of Ottawa. The trial, called MESCAMS [Mesenchymal Stem Cell Therapy for Canadian MS patients], will comprise MSC infusions to the central nervous system to utilize their ability to regulate autoimmune attacks and reduce inflammation in 40 MS patients.

While previous clinical trials in other countries have demonstrated human tolerance and the preliminary effectiveness of the mesenchymal stem cell treatment, this trial expands on previous knowledge and opens the door for other treatments to help Canadian patients suffering from a broad range of neurodegenerative diseases.  As stated by senior scientist Dr. Mark S. Freedman, “I’m very excited to be leading this study, which will provide more definitive answers for people living with multiple sclerosis.”

As personalized regenerative medicine advances, autologous stem cells will become an invaluable resource to families and individuals who seek to ensure that they will have access to the best in medical care should the need for it arise. One of the most convenient and affordable sources for recovering and banking your own stem cells is dental stem cells. To learn more about how to bank dental stem cells for use in future therapies and treatments, visit StemSave or call 877-783-6728 (877-StemSave) today.

 

 

To view the full article, click here.

 

 

The Future of Regenerative Medicine is Now.™